Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.67Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 23 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: 9.42%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive trajectory for Alnylam Pharmaceuticals, characterized by strong revenue growth and successful product launches. Despite some uncertainties related to regulatory policies and increased R&D expenses, the company's strategic focus on TTR leadership and sustainable financial performance supports a positive outlook.Company Guidance
During the Alnylam Pharmaceuticals Q1 2025 earnings call, the company provided guidance underscoring a strong start to the year with $469 million in combined net product revenues, marking a 28% year-over-year growth. This was primarily driven by a robust 45% growth in their U.S. TTR franchise. The company reiterated its full-year guidance, projecting a 36% year-over-year growth in TTR franchise revenues and emphasized its goal of achieving sustainable non-GAAP profitability by the end of 2025. The call highlighted the successful launch of AMVUTTRA for ATTR cardiomyopathy, with early signs of broad uptake and favorable patient access. Alnylam also announced ongoing pipeline advancements, including the initiation of pivotal studies and expected regulatory approvals in key markets.Strong Start to 2025
Alnylam Pharmaceuticals reported a strong start to 2025 with $469 million in combined net product revenues, representing 28% growth year-over-year. The U.S. TTR franchise saw robust 45% year-over-year growth driven by increased uptake in the hereditary polyneuropathy population.
Successful Product Launches
AMVUTTRA received expanded indication approvals in the U.S. and Brazil for ATTR cardiomyopathy, with a positive CHMP opinion in the EU. Additionally, Qfitlia for hemophilia A or B was approved, marking the sixth RNAi therapeutic discovered by Alnylam.
Strategic Focus and Future Growth
Alnylam's strategy centers on TTR leadership, growth through innovation, and strong financial performance. The company is on track to achieve sustainable non-GAAP profitability in 2025.
GB:0HD2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0HD2 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $260.21 | $264.30 | +1.57% |
Feb 13, 2025 | $264.50 | $264.03 | -0.18% |
Oct 31, 2024 | $284.94 | $266.68 | -6.41% |
Aug 01, 2024 | $236.63 | $263.11 | +11.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alnylam Pharmaceuticals (GB:0HD2) report earnings?
Alnylam Pharmaceuticals (GB:0HD2) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Alnylam Pharmaceuticals (GB:0HD2) earnings time?
Alnylam Pharmaceuticals (GB:0HD2) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Alnylam Pharmaceuticals stock?
The P/E ratio of Alnylam Pharma is N/A.
What is GB:0HD2 EPS forecast?
GB:0HD2 EPS forecast for the fiscal quarter 2025 (Q2) is -0.67.